R R

What Is Rapamune?

Rapamune is a prescription medication containing sirolimus, an immunosuppressant that inhibits the mammalian target of rapamycin pathway. It is approved to help prevent organ rejection in certain patients receiving kidney transplants and to treat lymphangioleiomyomatosis, a rare lung disease also called LAM. Rapamune is available as oral tablets and an oral solution. It reduces activity in immune and cell-growth pathways, requiring careful monitoring of drug concentrations, kidney health, and adverse effects. Rapamune carries boxed warnings for infection and malignancy risks associated with immunosuppression, and its use is not recommended in liver or lung transplant recipients.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rapamune?

Rapamune is a prescription medication containing sirolimus, an immunosuppressant that inhibits the mammalian target of rapamycin pathway. It is approved to help prevent organ rejection in certain patients receiving kidney transplants and to treat lymphangioleiomyomatosis, a rare lung disease also called LAM. Rapamune is available as oral tablets and an oral solution. It reduces activity in immune and cell-growth pathways, requiring careful monitoring of drug concentrations, kidney health, and adverse effects. Rapamune carries boxed warnings for infection and malignancy risks associated with immunosuppression, and its use is not recommended in liver or lung transplant recipients.

read more about rapamune ...

Copy this HTML:

Copy HTML Copied!

How Does Rapamune Work?

Rapamune contains sirolimus, which binds to the intracellular protein FKBP-12. This complex inhibits mammalian target of rapamycin complex 1, or mTORC1, a signaling pathway involved in cell growth, proliferation, and immune responses. In kidney transplant recipients, this activity reduces the proliferation of certain immune cells that would otherwise contribute to organ rejection. In lymphangioleiomyomatosis, mTOR inhibition can reduce abnormal cell-growth signaling associated with the disease. Sirolimus does not replace every other transplant medication or permanently cure LAM. Its immunosuppressive effects can increase susceptibility to infections and certain cancers.

What Conditions Does Rapamune Treat?

Rapamune is approved for prophylaxis of organ rejection in kidney transplant recipients aged 13 years and older who meet specific clinical requirements. It is used within individualized immunosuppressive regimens, with different approaches according to transplant rejection risk. Rapamune is also approved to treat lymphangioleiomyomatosis, a rare progressive lung disease involving abnormal smooth muscle-like cell growth. The medication is not recommended as immunosuppressive therapy following liver or lung transplantation because serious complications and increased mortality have been reported. A specialist evaluates transplant status, lung function, liver function, drug interactions, and infection risk before prescribing it.

How Should Rapamune Be Taken?

Rapamune is taken orally once daily, with or without food, but consistently in relation to meals. Kidney transplant regimens use an initial loading dose followed by maintenance dosing adjusted according to sirolimus blood trough concentrations and the accompanying immunosuppressive medications. For lymphangioleiomyomatosis, the recommended starting dose is 2 mg once daily, with adjustments to maintain appropriate trough concentrations. Tablets should be swallowed whole rather than crushed or chewed. The oral solution requires specific dilution instructions. Rapamune interacts with CYP3A4 and P-glycoprotein inhibitors or inducers, and grapefruit juice should be avoided. Regular blood testing helps guide dosing and monitor toxicity.

What Are the Side Effects and Warnings of Rapamune?

Common adverse effects include mouth ulcers, swelling, elevated cholesterol or triglycerides, headache, abdominal discomfort, and changes in blood cell counts. Serious risks include infections, lymphoma and other malignancies, impaired wound healing, kidney dysfunction, proteinuria, and noninfectious pneumonitis. Rapamune carries boxed warnings for immunosuppression-related complications and serious adverse outcomes in liver or lung transplant recipients. Angioedema, blood clots, and reproductive toxicity are additional concerns. Patients may require monitoring for infections, skin cancer, lipid abnormalities, and drug concentrations. Fever, persistent cough, breathing difficulty, severe swelling, or unusual wound problems require medical evaluation.

Common Questions About Rapamune

Is Rapamune the same as sirolimus?

Yes. Rapamune is a brand name for sirolimus, an mTOR inhibitor used for certain kidney transplant recipients and patients with lymphangioleiomyomatosis.

Can Rapamune prevent kidney transplant rejection?

Yes. Rapamune is approved to help prevent organ rejection in specified kidney transplant recipients as part of an immunosuppressive treatment regimen.

Is Rapamune used for lymphangioleiomyomatosis?

Yes. Rapamune is approved to treat lymphangioleiomyomatosis, a rare lung disease associated with abnormal cell growth.

Can Rapamune be used after a lung transplant?

Rapamune is not recommended as immunosuppressive therapy for lung transplant recipients because serious complications, including bronchial anastomotic dehiscence, have been reported.

References

DailyMed - SIROLIMUS tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e7aa7ef-665f-4dd4-a14b-b90949bb646f. Date Accessed November 3, 2026.

RAPAMUNE (sirolimus) Prescribing Information. Pfizer. https://labeling.pfizer.com/showlabeling.aspx?id=139. Date Accessed November 3, 2026.

Sirolimus. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548028/. Date Accessed November 3, 2026.

Sirolimus. MedlinePlus. https://medlineplus.gov/druginfo/meds/a602026.html. Date Accessed November 3, 2026.

Sirolimus. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/5284616. Date Accessed November 3, 2026.